(Total Views: 216)
Posted On: 07/10/2017 12:40:38 AM
Post# of 72447
In pre-revenue biotechs, trial results and partnerships are the major catalysts. Last year we saw the stock ran up to almost $2 in anticipation to the P P2a result. When management decided to run a P2b then look for a partner, some investors sold.
IPIX just didn't have a major catalyst for the past 12 months, but the second half will be a different story. We just saw the stock ran up from the 60s to over $1 in anticipation to the B-UP result. I bet we'll see a much bigger run-up in anticipation to the P P2b result, especially if the interim analysis is positive.
No doubt SP manipulations are going on daily. I know you watch them closely. The shorts are betting against the science, not smart considering Dr. Menon's track record.
IPIX just didn't have a major catalyst for the past 12 months, but the second half will be a different story. We just saw the stock ran up from the 60s to over $1 in anticipation to the B-UP result. I bet we'll see a much bigger run-up in anticipation to the P P2b result, especially if the interim analysis is positive.
No doubt SP manipulations are going on daily. I know you watch them closely. The shorts are betting against the science, not smart considering Dr. Menon's track record.
(1)
(0)
